EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report

Michael J Wilkinson iD, Priyesha Bijlani iD, Michael H Davidson, P Barton Duell iD, Mary Horan, Mary J Malloy iD, Ron S Newfield iD, Pallavi Pradeep, Prediman K Shah, Eveline O Stock iD, Bruce A Warden iD, Matthew K Ito

Arteriosclerosis, Thrombosis, and Vascular Biology · 2025

DOI: 10.1161/atvbaha.124.322364 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Michael J Wilkinson und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, La Jolla (M.J.W., P.B., R.S.N.). Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Cholesterol, LDL. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is an autosomal semidominant disorder characterized by extreme elevations in LDL-C (low-density lipoprotein cholesterol) and early-onset atherosclerotic cardiovascular disease. Evinacumab is a monoclonal antibody administered by monthly intravenous infusion that binds ANGPTL3 (angiopoietin-like 3) and when added to standard lipid-lowering therapies lowers LDL-C by ≈50% in HoFH clinical trials. Studies examining the real-world effectiveness and safety of evinacumab are limited. METHODS: We performed a retrospective study to assess the effectiveness and safety of evinacumab in patients with HoFH in clinical practice at 6 US academic medical centers. The primary end point was the percent change in LDL-C from baseline to first follow-up and to the most recent follow-up after evinacumab initiation. Secondary end points were percent change in non–high-density lipoprotein cholesterol (non–HDL-C), triglycerides, total cholesterol, HDL-C, and achievement of an LDL-C

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLHyperlipoproteinemia Type IIAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedYoung AdultAngiopoietin-Like Protein 3Angiopoietin-like ProteinsBiomarkersHomozygoteRetrospective StudiesTime FactorsTreatment OutcomeUnited StatesChild, PreschoolAged, 80 and over

Stichwörter der Autor:innen

cholesterolevinacumabfollow-up studieslipoproteinsretrospective studies

Substanzen

Angiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsBiomarkersCholesterol, LDLevinacumab

Autor:innen und Institutionen

  • University of California San Diego, La Jolla (M.J.W., P.B., R.S.N.).
  • University of Chicago, IL (M.H.D., M.H., P.P.).
  • Oregon Health & Science University, Portland (P.B.D., B.A.W.).
  • University of California San Francisco (M.J.M., E.O.S.).
  • Rady Children's Hospital, San Diego, CA (R.S.N.).
  • Cedars-Sinai Medical Center, Los Angeles, CA (P.K.S.).

ORCID-Profile: Michael J Wilkinson, Priyesha Bijlani, P Barton Duell, Mary J Malloy, Ron S Newfield, Eveline O Stock, Bruce A Warden

Zitieren

APA

Wilkinson, M. J., Bijlani, P., Davidson, M. H., Duell, P. B., Horan, M., Malloy, M. J., Newfield, R. S., Pradeep, P., Shah, P. K., Stock, E. O., Warden, B. A., & Ito, M. K. (2025). Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.322364

Vancouver

Wilkinson MJ, Bijlani P, Davidson MH, Duell PB, Horan M, Malloy MJ, et al. Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.322364

BibTeX
@article{Wilkinson2025,
  author = {Wilkinson, Michael J and Bijlani, Priyesha and Davidson, Michael H and Duell, P Barton and Horan, Mary and Malloy, Mary J and Newfield, Ron S and Pradeep, Pallavi and Shah, Prediman K and Stock, Eveline O and Warden, Bruce A and Ito, Matthew K},
  title = {Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2025},
  doi = {10.1161/atvbaha.124.322364}
}
Kostenlos starten →